We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$250M
1-Year Est. Return
77.6%
This Fund
S&P 500
This Quarter
Est. Return
+5.67%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$191M
AUM Growth
+$6.1M
(+3.3%)
Cap. Flow
+$4.9M
Cap. Flow
% of AUM
2.56%
Top 10 Holdings %
Top 10 Hldgs %
79.09%
Holding
32
New
3
Increased
11
Reduced
12
Closed
5
Top Buys
| 1 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$10.4M |
| 2 |
SBBP
Strongbridge Biopharma plc.
SBBP
|
+$7.55M |
| 3 |
CHMA
Chiasma, Inc. Common Stock
CHMA
|
+$6.89M |
| 4 |
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
|
+$3.4M |
| 5 |
Gyre Therapeutics
GYRE
|
+$2.87M |
Top Sells
| 1 |
KALV
KalVista Pharmaceuticals
KALV
|
+$5.82M |
| 2 |
DiaMedica Therapeutics
DMAC
|
+$4.95M |
| 3 |
APEN
Apollo Endosurgery, Inc.
APEN
|
+$4.71M |
| 4 |
PLXP
PLx Pharma Inc. Common Stock
PLXP
|
+$4.57M |
| 5 |
ADMS
Adamas Pharmaceuticals
ADMS
|
+$3.75M |
Sector Composition
| 1 | Healthcare | 88.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AMYT
1
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $33.9M | 17.75% |
2,797,744
+274,016
| +11% | +$3.4M |
|
|
CHMA
2
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $32M | 16.75% |
6,770,000
+1,829,727
| +37% | +$6.89M |
|
|
CTIC
3
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $19.1M | 9.98% |
7,632,530
+4,339,111
| +132% | +$10.4M |
|
|
ADMS
4
DELISTED
Adamas Pharmaceuticals
ADMS
| $14.2M | 7.44% |
2,694,295
-723,984
| -21% | -$3.75M |
|
|
5
Gyre Therapeutics
GYRE
$675M
| $13.3M | 6.97% |
410,183
+83,491
| +26% | +$2.87M |
|
|
SBBP
6
DELISTED
Strongbridge Biopharma plc.
SBBP
| $9.82M | 5.13% |
3,305,617
+2,859,916
| +642% | +$7.55M |
|
7
Ovid Therapeutics
OVID
$455M
| $7.82M | 4.09% |
2,000,000
-483,059
| -19% | -$1.91M |
|
|
CFMS
8
DELISTED
Conformis, Inc. Common Stock
CFMS
| $7.62M | 3.98% |
265,043
+87,771
| +50% | +$2.07M |
|
|
AFMD
9
DELISTED
Affimed
AFMD
| $7.22M | 3.78% |
85,000
-18,000
| -17% | -$1.64M |
|
|
APEN
10
DELISTED
Apollo Endosurgery, Inc.
APEN
| $6.17M | 3.23% |
762,183
-686,685
| -47% | -$4.71M |
|
|
XOMA
11
DELISTED
Xoma
XOMA
| $5.61M | 2.93% |
165,041
+1,775
| +1% | +$59.5K |
|
12
Celcuity
CELC
$4.31B
| $5.25M | 2.75% |
218,951
+109,870
| +101% | +$2.83M |
|
|
KA
13
DELISTED
Kineta, Inc. Common Stock
KA
| $5.15M | 2.69% |
63,137
+15,173
| +32% | +$1.64M |
|
|
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
| $4.79M | 2.51% |
200,000
-222,310
| -53% | -$5.82M |
|
|
ISEE
15
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $3.27M | 1.71% |
517,445
-357,735
| -41% | -$2.31M |
|
16
Elicio Therapeutics
ELTX
$81.7M
| $2.9M | 1.52% |
22,284
+8,786
| +65% | +$1.27M |
|
|
GMDA
17
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $2.84M | 1.49% |
443,507
+198,992
| +81% | +$1.37M |
|
18
EyePoint Inc
EYPT
$1.12B
| $2.73M | 1.43% |
303,851
-25,279
| -8% | -$243K |
|
19
Exagen
XGN
$106M
| $2.54M | 1.33% |
169,542
-21,464
| -11% | -$329K |
|
|
CDTX
20
DELISTED
Cidara Therapeutics
CDTX
| $2.45M | 1.28% |
+60,564
| New | +$2.56M |
|
|
21
DiaMedica Therapeutics
DMAC
$393M
| $1.87M | 0.98% |
419,942
-603,467
| -59% | -$4.95M |
|
|
CFRX
22
DELISTED
ContraFect Corporation
CFRX
| $296K | 0.15% |
840
-2,524
| -75% | -$826K |
|
|
NBSE
23
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $149K | 0.08% |
+1,554
| New | +$172K |
|
24
Corvus Pharmaceuticals
CRVS
$1.25B
| $125K | 0.07% |
46,886
-269,393
| -85% | -$742K |
|
|
AGTC
25
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $4K | ﹤0.01% |
1,000
-178,511
| -99% | -$740K |
|
Similar funds
BIA
TGP
ER
FDDB
VM
PF
SCM
CWM
Stonepine Capital Management's Q2 2021 Portfolio in Review
As of Q2 2021, Stonepine Capital Management held 32 positions worth $191M, up 3.3% from $185M the previous quarter. Its ten largest holdings account for 79% of the portfolio.
Stonepine Capital Management's Q2 2021 filing shows 3 new, 11 increased, 12 reduced and 5 closed positions. Its largest new stake was Cidara Therapeutics: 60,564 shares worth $2.45M. The largest sale was KalVista Pharmaceuticals, an estimated $5.82M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 89% a quarter earlier.
- Stonepine Capital Management's largest Q2 2021 buy was Cidara Therapeutics: 60,564 shares worth $2.45M.
- Stonepine Capital Management added most to CTI BioPharma Corp. (DE) Common Stock in Q2 2021, an estimated $10.4M increase.
- Stonepine Capital Management's biggest Q2 2021 reduction was KalVista Pharmaceuticals, cutting an estimated $5.82M.
- Stonepine Capital Management fully exited PLx Pharma Inc. Common Stock in Q2 2021, selling an estimated $4.57M.
- Stonepine Capital Management's ten largest holdings make up 79% of its $191M portfolio in Q2 2021.
- Stonepine Capital Management opened 3 new positions and closed 5 in Q2 2021.
- Stonepine Capital Management's portfolio value rose 3.3% quarter-over-quarter to $191M.
Based on Stonepine Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.